Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Your saved research and appointment questionsView recorded trial and retraction changes
Multiple Acyl-CoA Dehydrogenase Deficiency — Research Summary
Printed from RareWays (rareways.org) on 26 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Acquired multiple acyl-CoA dehydrogenase deficiency (MADD) provoked by sertraline: an emerging and treatable disorder.
Alungulese Anca Loredana et al. — Practical neurology (20 September 2026)
https://pubmed.ncbi.nlm.nih.gov/41633825/
- 2.
Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD / Glutaric Acidemia Type IIC) Presenting as Chronic Sensory Ataxic Ganglionopathy, Bilateral Sensorineural Hearing Loss, and Vocal Cord Dysfunction Associated with a Novel ETFDH Variant
B. B. Likhitha et al. — Asian Journal of Research in Medical and Pharmaceutical Sciences (11 September 2026)
https://doi.org/10.9734/ajrimps/2026/v15i3412
- 3.
ETFDH Gene Mutations in Multiple Acyl-CoA Dehydrogenase Deficiency (MADD): A Systematic Review
Armita Kakavand Hamidi et al. — Open Science Framework (4 September 2026)
https://doi.org/10.17605/osf.io/ejmfk
- 4.
A Family Exhibiting Autosomal Dominant Inheritance of Multiple Acyl-Coenzyme A (CoA) Dehydrogenase Deficiency (MADD) Disease.
Baldo Francesco et al. — International journal of molecular sciences (15 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42653298/
- 5.
Genotype-environment interaction drives the onset of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency in carriers of single heterozygous ETFDH variants.
Ma Jing et al. — Cell communication and signaling : CCS (2 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42231330/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Multiple Acyl-CoA Dehydrogenase Deficiency
Multiple acyl-CoA dehydrogenase deficiency, also called glutaric acidaemia type 2, is an inherited condition in which the body cannot properly break down fats and some proteins for energy. It can cause low blood sugar, muscle weakness and episodes of illness, ranging from severe newborn forms to milder forms appearing later. Management includes a low-fat diet, avoiding fasting, carnitine and, for many people, riboflavin supplements.
Most Recent Research
Common Questions
What is Multiple Acyl-CoA Dehydrogenase Deficiency?
Multiple acyl-CoA dehydrogenase deficiency, also called glutaric acidaemia type 2, is an inherited condition in which the body cannot properly break down fats and some proteins for energy. It can cause low blood sugar, muscle weakness and episodes of illness, ranging from severe newborn forms to milder forms appearing later. Management includes a low-fat diet, avoiding fasting, carnitine and, for many people, riboflavin supplements.
How many clinical trials are available for Multiple Acyl-CoA Dehydrogenase Deficiency?
No clinical trials are currently indexed for Multiple Acyl-CoA Dehydrogenase Deficiency. This may change as new trials are registered. Check back regularly or visit ClinicalTrials.gov directly.
Where does the research data for Multiple Acyl-CoA Dehydrogenase Deficiency come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Multiple Acyl-CoA Dehydrogenase Deficiency.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.